Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 3/20 | 0.64 |
| ▸ | EDNRB | P24530 | 2/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PPIA | P62937 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14484171 | 0.91 | MEN1 (0.58) | KMT2ATSHRMAPK1MAPTALDH1A1 | |
| SCHEMBL5334733 | 0.79 | EDNRB (0.64) | EDNRAEDNRBKMT2ATSHRMAPT | |
| SCHEMBL7860462 | 0.78 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL3937403 | 0.77 | HSD11B1 (1.00) | EDNRAEDNRBHSD11B1MAPK1MAPT | |
| SCHEMBL5183416 | 0.77 | ALDH1A1 (0.61) | EDNRAKMT2ATSHRMAPK1MAPT | |
| SCHEMBL7716873 | 0.77 | ALDH1A1 (0.54) | EDNRAEDNRBKMT2ATSHRMAPK1 | |
| SCHEMBL3923771 | 0.77 | HSD11B1 (0.73) | EDNRAEDNRBHSD11B1KMT2ATSHR | |
| SCHEMBL5305344 | 0.76 | RORA (0.50) | KMT2ATSHRMAPK1MAPTALDH1A1 | |
| SCHEMBL7591248 | 0.76 | HSD11B1 (0.63) | EDNRAEDNRBHSD11B1SLC40A1 | |
| SCHEMBL6027188 | 0.75 | HSD11B1 (0.75) | EDNRAEDNRBHSD11B1MAPTSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1843772-A1 | INTRAVENOUS FORMULATIONS OF PDE-5 INHIBITORS | Bayer HealthCare AG (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| WO-2006074872-A1 | INTRAVENOUS FORMULATIONS OF PDE-5 INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-07-20 | — | — | WO | disclosed |
| EP-1675844-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005042513-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | STERIX LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD17B3 | EDNRA 609/4885EDNRB 396/4885HSD11B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.